Iterum Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference
06 avr. 2021 08h30 HE
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, April 06, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics Appoints Beth P. Hecht to Board of Directors
16 mars 2021 07h30 HE
|
Iterum Therapeutics plc
Patrick Heron to leave the Board DUBLIN, Ireland and CHICAGO, March 16, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum”), a clinical-stage pharmaceutical...
Iterum Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results
12 mars 2021 07h00 HE
|
Iterum Therapeutics plc
--NDA for Oral Sulopenem has PDUFA date of July 25, 2021-- --Cash Runway into First Half of 2023— --Company to host conference call today at 8:30amET-- DUBLIN, Ireland and CHICAGO, March 12,...
Iterum Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call on March 12, 2021
05 mars 2021 17h30 HE
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, March 05, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics to Present in Upcoming Investor Conferences
19 févr. 2021 17h30 HE
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics plc Announces Exercise of Underwriter’s Option to Purchase Additional Ordinary Shares
10 févr. 2021 18h40 HE
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics plc Announces $35.0 Million Registered Direct Offering of Ordinary Shares Priced At-the-Market under Nasdaq Rules
09 févr. 2021 23h58 HE
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics plc Increases Previously Announced Bought Deal Public Offering of Ordinary Shares to $40.0 Million
03 févr. 2021 23h35 HE
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics plc Announces $10 Million Bought Deal Public Offering of Ordinary Shares
03 févr. 2021 17h51 HE
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics Announces Collaboration with EVERSANA to Support Oral Sulopenem Launch
01 févr. 2021 07h00 HE
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation...